{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-23-000060","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.164265+00:00","generated_at":"2026-06-11T21:22:02.691432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Illumina Q2 revenue up 1% to $1.18B, non-GAAP EPS $0.32, ships 109 NovaSeq X; guides FY23 non-GAAP EPS $0.75-0.90","bullets":["Revenue $1.176B (+1% YoY, +8% QoQ); GAAP loss per share $(1.48) vs $(3.40) (incl. $609M legal contingency).","Non-GAAP diluted EPS $0.32 vs $0.57; non-GAAP gross margin 66.5% vs 69.4%.","Shipped 109 NovaSeq X instruments in Q2; FY2023 supply capacity now >390 instruments.","FY2023 guidance: rev growth ~1%, GAAP loss $(2.08)-(1.93), non-GAAP EPS $0.75-$0.90.","Headwinds: cautious customer spending, slow China recovery, temporary decline in high-throughput consumables."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-23-000060","json":"https://secwatch.observer/filing/0001110803-23-000060.json","markdown":"https://secwatch.observer/filing/0001110803-23-000060.md","text":"https://secwatch.observer/filing/0001110803-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080323000060/0001110803-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080323000060/ilmn-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:22:02.691432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f053a543c0c44fadf931670fb010a5d517417b53","claim":"ILLUMINA, INC. reported the second quarter ended July 2, 2023 results: revenue $1.18 billion. Guidance reaffirmed.","evidence_excerpt":"+1.858.291.6421 ir@illumina.com Media: David McAlpine +1.347.327.1336 pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023 • Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 • Shipped 109 NovaSeq X instruments in Q2 2023; boosting our supply capacity to more","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1110803/000111080323000060/0001110803-23-000060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended July 2, 2023"},{"label":"Revenue","value":"$1.18 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}